These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
79 related articles for article (PubMed ID: 2445936)
1. The pharmacology of intraperitoneally administered bleomycin. Howell SB; Schiefer M; Andrews PA; Markman M; Abramson I J Clin Oncol; 1987 Dec; 5(12):2009-16. PubMed ID: 2445936 [TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of intraperitoneally administered dipyridamole in cancer patients. Chan TC; Coppoc GL; Zimm S; Cleary S; Howell SB Cancer Res; 1988 Jan; 48(1):215-8. PubMed ID: 3334996 [TBL] [Abstract][Full Text] [Related]
3. Intraperitoneal chemotherapy with melphalan. Howell SB; Pfeifle CE; Olshen RA Ann Intern Med; 1984 Jul; 101(1):14-8. PubMed ID: 6732077 [TBL] [Abstract][Full Text] [Related]
4. Phase I clinical and pharmacological study of iododeoxyuridine and bleomycin in patients with advanced cancer. Schilsky RL; Janisch L; Berezin F; Mick R; Vogelzang NJ; Ratain MJ Cancer Res; 1993 Mar; 53(6):1293-6. PubMed ID: 7680282 [TBL] [Abstract][Full Text] [Related]
5. Phase I clinical and pharmacokinetic study of thiotepa administered intraperitoneally in patients with advanced malignancies. Wadler S; Egorin MJ; Zuhowski EG; Tortorello L; Salva K; Runowicz CD; Wiernik PH J Clin Oncol; 1989 Jan; 7(1):132-9. PubMed ID: 2491884 [TBL] [Abstract][Full Text] [Related]
6. Ip chemotherapy employing a regimen of cisplatin, cytarabine, and bleomycin. Markman M; Cleary S; Lucas W; Weiss R; Howell SB Cancer Treat Rep; 1986 Jun; 70(6):755-60. PubMed ID: 2425962 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic study of intraperitoneal streptozotocin. Goel R; McClay EF; Kirmani S; Kim S; Braly PF; Plaxe SC; Alcaraz J; Andrews PA; Reichman B; Markman M Clin Invest Med; 1992 Oct; 15(5):420-6. PubMed ID: 1458714 [TBL] [Abstract][Full Text] [Related]
8. Phase I and pharmacologic studies of intraperitoneal leucovorin and 5-fluorouracil in patients with advanced cancer. Arbuck SG; Trave F; Douglass HO; Nava H; Zakrzewski S; Rustum YM J Clin Oncol; 1986 Oct; 4(10):1510-7. PubMed ID: 3489819 [TBL] [Abstract][Full Text] [Related]
9. Phase I trial of intraperitoneal docetaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity: dose-limiting toxicity and pharmacokinetics. Morgan RJ; Doroshow JH; Synold T; Lim D; Shibata S; Margolin K; Schwarz R; Leong L; Somlo G; Twardowski P; Yen Y; Chow W; Lin P; Paz B; Chu D; Frankel P; Stalter S Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5896-901. PubMed ID: 14676112 [TBL] [Abstract][Full Text] [Related]
10. Bleomycin clinical pharmacology by radioimmunoassay. Hall SW; Strong JE; Broughton A; Frazier ML; Benjamin RS Cancer Chemother Pharmacol; 1982; 9(1):22-5. PubMed ID: 6183016 [TBL] [Abstract][Full Text] [Related]
11. Phase I clinical and pharmacologic study of intraperitoneal cisplatin and fluorouracil in patients with advanced intraabdominal cancer. Schilsky RL; Choi KE; Grayhack J; Grimmer D; Guarnieri C; Fullem L J Clin Oncol; 1990 Dec; 8(12):2054-61. PubMed ID: 2230897 [TBL] [Abstract][Full Text] [Related]
12. Clinical pharmacology of bleomycin following intravenous infusion as determined by radioimmunoassay. Broughton A; Strong JE; Holoye PY; Bedrossian CW Cancer; 1977 Dec; 40(6):2772-8. PubMed ID: 73408 [TBL] [Abstract][Full Text] [Related]
13. Effects of variations in renal function on the clinical pharmacology of bleomycin administered as an iv bolus. Crooke ST; Comis RL; Einhorn LH; Strong JE; Broughton A; Prestayko AW Cancer Treat Rep; 1977 Dec; 61(9):1631-6. PubMed ID: 74282 [TBL] [Abstract][Full Text] [Related]
14. Phase I/pharmacokinetic study of thioguanine administered as a 48-hour continuous intraperitoneal infusion. Zimm S; Cleary SM; Horton CN; Howell SB J Clin Oncol; 1988 Apr; 6(4):696-700. PubMed ID: 3357007 [TBL] [Abstract][Full Text] [Related]
15. Phase I and pharmacological studies of 5-fluorouracil administered intraperitoneally. Speyer JL; Collins JM; Dedrick RL; Brennan MF; Buckpitt AR; Londer H; DeVita VT; Myers CE Cancer Res; 1980 Mar; 40(3):567-72. PubMed ID: 7471076 [TBL] [Abstract][Full Text] [Related]
17. Phase I trial of intraperitoneal iododeoxyuridine with and without intravenous high-dose folinic acid in the treatment of advanced malignancies primarily confined to the peritoneal cavity: flow cytometric and pharmacokinetic analysis. Morgan RJ; Newman EM; Doroshow JH; McGonigle K; Margolin K; Raschko J; Chow W; Somlo G; Leong L; Tetef M; Shibata S; Hamasaki V; Carroll M; Vasilev S; Akman S; Coluzzi P; Wagman L; Longmate J; Paz B; Yen Y; Klevecz R Cancer Res; 1998 Jul; 58(13):2793-800. PubMed ID: 9661893 [TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic advantage of intraperitoneal injection of docetaxel in the treatment for peritoneal dissemination of cancer in mice. Shimada T; Nomura M; Yokogawa K; Endo Y; Sasaki T; Miyamoto K; Yonemura Y J Pharm Pharmacol; 2005 Feb; 57(2):177-81. PubMed ID: 15720780 [TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and tissue distribution of intraperitoneal paclitaxel with different carrier solutions. Mohamed F; Marchettini P; Stuart OA; Sugarbaker PH Cancer Chemother Pharmacol; 2003 Nov; 52(5):405-10. PubMed ID: 12879282 [TBL] [Abstract][Full Text] [Related]
20. Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot Study. Francis P; Rowinsky E; Schneider J; Hakes T; Hoskins W; Markman M J Clin Oncol; 1995 Dec; 13(12):2961-7. PubMed ID: 8523061 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]